Cite
Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA/IELSG36 study.
MLA
Iannitto, Emilio, et al. “Efficacy of Bendamustine and Rituximab in Splenic Marginal Zone Lymphoma: Results from the Phase II BRISMA/IELSG36 Study.” British Journal of Haematology, vol. 183, no. 5, Dec. 2018, pp. 755–65. EBSCOhost, https://doi.org/10.1111/bjh.15641.
APA
Iannitto, E., Bellei, M., Amorim, S., Ferreri, A. J. M., Marcheselli, L., Cesaretti, M., Haioun, C., Mancuso, S., Bouabdallah, K., Gressin, R., Tripodo, C., Traverse, G. A., Baseggio, L., Zupo, S., Stelitano, C., Castagnari, B., Patti, C., Alvarez, I., Liberati, A. M., & Merli, M. (2018). Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA/IELSG36 study. British Journal of Haematology, 183(5), 755–765. https://doi.org/10.1111/bjh.15641
Chicago
Iannitto, Emilio, Monica Bellei, Sandy Amorim, Andrés J. M. Ferreri, Luigi Marcheselli, Marina Cesaretti, Corinne Haioun, et al. 2018. “Efficacy of Bendamustine and Rituximab in Splenic Marginal Zone Lymphoma: Results from the Phase II BRISMA/IELSG36 Study.” British Journal of Haematology 183 (5): 755–65. doi:10.1111/bjh.15641.